RemeGen Co., Ltd. released a monthly update on its share capital for the period ended 31 January 2026. The authorized share capital for H shares remained at 208.58 million shares, while authorized A shares increased from 355.13 million shares to 355.90 million shares. Overall, the total authorized capital reached 564.48 million RMB.

No changes were recorded in the issued H shares, which stayed at 208.58 million shares with no treasury shares. For A shares, the issued portion rose by 0.57 million shares to 355.70 million shares, and treasury shares stood at 0.19 million shares at the end of the month.

The company attributed part of the changes to its A share incentive schemes announced previously. The relevant restricted shares were granted and lapsed according to their respective terms. The announced repurchase of certain A shares for the employee equity incentive program during January 2026 contributed to an increase in treasury shares. The public float requirement for H shares remained in compliance, with the listed H shares meeting the applicable threshold of 5%.